But nearly half of Merck's revenue is generated by a single product. That's oncology drug Keytruda, which has turned out to ...

Merck’s investigational antibody MK-2214 has received fast-track designation from the FDA for the treatment of Alzheimer’s disease. MK-2214 targets phosphorylated serine 413 tau (pS413), a marker of ...

Merck & Co., one of the world's oldest pharmaceutical manufacturers, is cutting 204 positions in its home state as part of a ...

Germany's Merck KGaA on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration focused ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

Merck reported second-quarter revenue and adjusted earnings that topped estimates as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and ...

Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer discussed, along with the tech battleground. Cramer highlighted ...

(Reuters) - Pfizer Inc and Merck & Co Inc said they will co-develop Pfizer's experimental type 2 diabetes drug ertugliflozin, both as a standalone product and in combination with other drugs, ...

WASHINGTON (AP) -- The Food and Drug Administration said Thursday it is investigating a possible link between Merck's best-selling Singulair and suicide. FDA said it is reviewing a handful of reports ...

Merck's MK-2214 drug received fast-track designation from the Food and Drug Administration for treatment of Alzheimer's disease. The Rahway, N.J., company said Monday that it would present data this ...